Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:31 PM ET 8-K
Financial Results Indaptus Therapeutics, Inc. INDP

Indaptus Therapeutics Financial Results

Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.

“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board

“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
4:31 PM ET Form 4
Insider Selling Luckin Coffee Inc. LKNCY

Luckin Coffee CEO Jinyi Guo Sells $7.29M of Stock

Jinyi Guo, CEO, sold 200,000 shares of Luckin Coffee Inc. at $36.44 a share, worth $7.29M in total on Nov 11, 2026. Shares held after the trade: 2,563,000 (-7.2%).

Value
$7.29M
Shares
200,000
Price
$36.44
Role
CEO
Holding change
-7.2%
Trade date
Nov 11, 2026
4:31 PM ET Form 4
Insider Buying Trinity Capital Inc. TRIN

Trinity Capital CEO, President and CIO Kyle Steven Brown Buys $58K of Stock

Kyle Steven Brown, CEO, President and CIO, bought 3,215 shares of Trinity Capital Inc. at $18.04 a share, worth $58K in total on Nov 11, 2026. Shares held after the trade: 654,878 (+0.5%).

Value
$58K
Shares
3,215
Price
$18.04
Role
CEO, President and CIO
Holding change
+0.5%
Trade date
Nov 11, 2026
4:31 PM ET 8-K
Deal Termination WinVest Acquisition Corp. WINV

WinVest Acquisition Deal Termination with Embed Financial Group Holdings

Winvest Acquisition Corp. mutually agreed to terminate its previously announced business combination agreement with Embed Financial Group Holdings, effective November 9, 2026. As a result of the termination, the planned merger transactions were abandoned and all related ancillary documents were cancelled. The parties have entered into a mutual release of all claims and liabilities related to the transaction.

Counterparty
Embed Financial Group Holdings
4:31 PM ET 8-K
Leadership Change Algorhythm Holdings, Inc. RIME

Algorhythm Holdings Leadership Change

Ryan J. Smith has transitioned from Chief Operating Officer to Delivery Project Executive as part of an internal restructuring of Azure Energy. As a result of this change in responsibilities, he is no longer considered an executive officer, and the company does not currently intend to appoint a successor COO.

4:31 PM ET Form 4
Insider Selling First Advantage Corp FA

First Advantage Director Slta V (Gp) L.L.C. Sells $324M of Stock

Slta V (Gp) L.L.C., Director, sold 15,000,000 shares of First Advantage Corp at $21.60 a share, worth $324M in total on Nov 12, 2026. Shares held after the trade: 52,846,632 (-22.1%).

Value
$324M
Shares
15,000,000
Price
$21.60
Role
Director
Holding change
-22.1%
Trade date
Nov 12, 2026
4:31 PM ET Form 4
Insider Selling Enova International, Inc. ENVA

Enova International Director Linda Johnson Rice Sells $204K of Stock

Linda Johnson Rice, Director, sold 1,200 shares of Enova International, Inc. at $170.00 a share, worth $204K in total on Nov 11, 2026. Shares held after the trade: 5,077 (-19.1%).

Value
$204K
Shares
1,200
Price
$170.00
Role
Director
Holding change
-19.1%
Trade date
Nov 11, 2026
4:31 PM ET Form 4
Insider Selling Beta Technologies, Inc. BETA

Beta Technologies COO Sean Donovan Sells $651K of Stock

Sean Donovan, COO, sold 23,167 shares of Beta Technologies, Inc. at $28.01 to $28.38 a share (average $28.12) in 2 transactions, worth $651K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 240,972 (-2.7%).

Value
$651K
Shares
23,167
Average price
$28.12
Role
COO
Holding change
-2.7%
Trade date
Nov 10, 2026 to Nov 11, 2026
4:31 PM ET Form 4
Insider Selling Intercontinental Exchange, Inc. ICE

Intercontinental Exchange CTO Mayur Kapani Sells $765K of Stock

Mayur Kapani, CTO, sold 4,272 shares of Intercontinental Exchange, Inc. at $176.90 to $180.31 a share (average $179.05) in 4 transactions, worth $765K in total on Nov 11, 2026. Shares held after the trade: 69,480 (-0.8%).

Value
$765K
Shares
4,272
Average price
$179.05
Role
CTO
Holding change
-0.8%
Trade date
Nov 11, 2026
4:31 PM ET Form 4
Insider Selling Corcept Therapeutics Inc CORT

Corcept Therapeutics Director Daniel N. Swisher Jr. Sells $111K of Stock

Daniel N. Swisher Jr., Director, sold 1,500 shares of Corcept Therapeutics Inc at $74.07 a share, worth $111K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).

Value
$111K
Shares
1,500
Price
$74.07
Role
Director
Holding change
-100.0%
Trade date
Nov 10, 2026
4:31 PM ET 8-K
Financial Results IRulya Therapeutics Inc. IRLA

IRulya Therapeutics Financial Results

IRulya Therapeutics (formerly Quince Therapeutics) reported Q3 2026 financial results and provided a corporate update following its recent rebranding and leadership appointments. The company ended the quarter with $105.2 million in cash, which is expected to fund operations through 2028, supporting Phase 2 clinical readouts for its lead candidate LAM-001 in pulmonary diseases.

Term
Q3 2026

“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases. By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”

Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
4:31 PM ET 10-Q
Financial Results TPG Private Equity Opportunities, L.P.

TPG Private Equity Opportunities Q3 2026 Results: Net Income $94M, Up 165.1% YoY

TPG Private Equity Opportunities, L.P. is an emerging growth company that invests primarily through the T-POP US Aggregator (CYM), L.P. As of November 10, 2026, the fund had approximately 62.3 million limited partnership units outstanding across seven different classes, including Class I and Class R-S as the largest components.

Key figure
Net income $94M · +165.1% YoY
4:30 PM ET Form 4
Insider Buying Four Corners Property Trust, Inc. FCPT

Four Corners Property Trust President and CEO William H. Lenehan Buys $150K of Stock

William H. Lenehan, President and CEO, bought 6,468 shares of Four Corners Property Trust, Inc. at $23.19 a share, worth $150K in total on Nov 13, 2026. Shares held after the trade: 796,325 (+0.8%).

Value
$150K
Shares
6,468
Price
$23.19
Role
President and CEO
Holding change
+0.8%
Trade date
Nov 13, 2026
4:30 PM ET Form 4
Insider Selling Genius Sports Ltd GENI

Genius Sports Chief Commercial Officer Jack Davison Sells $184K of Stock

Jack Davison, Chief Commercial Officer, sold 30,000 shares of Genius Sports Ltd at $6.14 a share, worth $184K in total on Nov 12, 2026. Shares held after the trade: 1,999,706 (-1.5%).

Value
$184K
Shares
30,000
Price
$6.14
Role
Chief Commercial Officer
Holding change
-1.5%
Trade date
Nov 12, 2026
4:30 PM ET 10-Q
Financial Results Evernorth Holdings Inc. XRPN

Evernorth Holdings Q3 2026 Results: Turns Profitable, Net Income $155M

Evernorth Holdings Inc. reported its third-quarter 2026 financial results, highlighting continued growth in its pharmacy benefit management and specialty pharmacy segments. The filing indicates a focus on expanding specialty pharmacy capabilities and managing medical cost trends effectively while maintaining stable full-year guidance.

Key figure
Net income $155M
4:30 PM ET 8-K
Stock Buyback Boston Omaha Corp BOC

Boston Omaha Announces $85M Stock Buyback

Boston Omaha Corporation's Board of Directors has voted to significantly increase its share repurchase program from $30 million to $85 million. The program allows for repurchases of Class A common stock through open market or private transactions and is set to expire on December 31, 2027. The company intends to fund the buybacks using available cash and cash equivalents.

Value
$85M
Term
through Dec 2027
4:30 PM ET 10-Q
Financial Results Egain Corp EGAN

Egain Q1 2026 Results: Net Income $1.55M, Down 45.0% YoY

For the quarter ended September 30, 2026, eGain reported total revenue of $21.9 million, a decrease from $23.5 million in the prior year, primarily driven by lower SaaS and professional services revenue. Net income declined to $1.55 million ($0.06 per diluted share) compared to $2.82 million ($0.10 per diluted share) in the same period last year. The company continued its share repurchase program, spending $3.6 million to buy back 644,000 shares during the quarter.

Key figure
Net income $1.55M · -45.0% YoY
4:30 PM ET 8-K/A
Financial Results NIQ Global Intelligence plc NIQ

NIQ Global Intelligence Financial Results

NIQ Global Intelligence reported Q3 2026 financial results, achieving positive GAAP EPS for the first time since its IPO with net income of $35.8 million. The company exceeded guidance across all key metrics, raised its full-year 2026 outlook, and announced a new $150 million share repurchase authorization after reaching its net leverage target ahead of schedule.

“Q3 was a milestone quarter — we exceeded the top end of our guidance across all key metrics for the sixth consecutive quarter, delivered positive GAAP earnings per share for the first time since our IPO, and reached our net leverage milestone a quarter ahead of plan.”

Jim Peck, Executive Chairman and Chief Executive Officer
4:30 PM ET 10-Q
Financial Results Core University Living Real Estate Income Trust

Core University Living Real Estate Income Trust Q3 2026 Results: Net Loss of $2.03M

Core University Living Real Estate Income Trust commenced operations in July 2026, acquiring an initial portfolio of four student housing properties for approximately $300.5 million. For the period from formation through September 30, 2026, the company reported a net loss of $2.8 million on rental revenues of $6.3 million, primarily due to depreciation, interest expense, and general and administrative costs.

Key figure
Net loss $2.03M
4:28 PM ET 8-K
Reverse Stock Split PharmaCyte Biotech, Inc. PMCB

PharmaCyte Biotech Reverse Stock Split

PharmaCyte Biotech implemented a 1-for-19 reverse stock split of its common stock effective November 12, 2026. The split consolidated approximately 10.8 million outstanding shares into roughly 0.57 million shares to increase the per-share trading price. The action is intended to help the company regain compliance with the Nasdaq minimum bid price requirement for continued listing.

4:28 PM ET 10-Q
Financial Results Hashdex Nasdaq CME Crypto Index ETF NCIQ

Hashdex Nasdaq CME Crypto Index ETF Q3 2026 Results: Net Income $125M, Up 661.9% YoY

As of September 30, 2026, the Hashdex Nasdaq CME Crypto Index ETF reported net assets of $498.3 million, a significant increase from $121.3 million at the end of 2025. The Trust's portfolio is heavily weighted in Bitcoin (73.79%) and Ethereum (11.98%), and it recently transitioned its reference index to the Nasdaq CME Crypto Settlement Price Index in January 2026.

Key figure
Net income $125M · +661.9% YoY
4:28 PM ET Form 4
Insider Selling Icu Medical Inc ICUI

Icu Medical Insider Elisha W. Finney Sells $316K of Stock

Elisha W. Finney sold 1,765 shares of Icu Medical Inc at $179.00 a share, worth $316K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 4,871 (-25.9%).

Value
$316K
Shares
1,765
Average price
$179.00
Holding change
-25.9%
Trade date
Nov 12, 2026 to Nov 13, 2026
4:28 PM ET Form 4
Insider Selling Arxis, Inc. ARXS

Arxis Insider Ross Bradley Sealfon Sells $783K of Stock

Ross Bradley Sealfon sold 15,000 shares of Arxis, Inc. at $51.44 to $53.03 a share (average $52.23) in 3 transactions, worth $783K in total on Nov 11, 2026. Shares held after the trade: 1,087,807 (-0.4%).

Value
$783K
Shares
15,000
Average price
$52.23
Holding change
-0.4%
Trade date
Nov 11, 2026
4:28 PM ET Form 4
Insider Buying Altimmune, Inc. ALT

Altimmune CFO Gregory L. Weaver Buys $16.2K of Stock

Gregory L. Weaver, CFO, bought 10,000 shares of Altimmune, Inc. at $1.62 a share, worth $16.2K in total on Nov 13, 2026. Shares held after the trade: 73,005 (+15.9%).

Value
$16.2K
Shares
10,000
Price
$1.62
Role
CFO
Holding change
+15.9%
Trade date
Nov 13, 2026
4:27 PM ET Form 4
Insider Selling Cavco Industries, Inc. CVCO

Cavco Industries President,Manufactured Housing Brian R. Cira Sells $1.59M of Stock

Brian R. Cira, President,Manufactured Housing, sold 2,382 shares of Cavco Industries, Inc. at $666.91 a share, worth $1.59M in total on Nov 10, 2026. Shares held after the trade: 1,908 (-55.5%).

Value
$1.59M
Shares
2,382
Price
$666.91
Role
President,Manufactured Housing
Holding change
-55.5%
Trade date
Nov 10, 2026
4:27 PM ET Form 4
Insider Buying Altimmune, Inc. ALT

Altimmune Director Wayne Pisano Buys $16.4K of Stock

Wayne Pisano, Director, bought 10,000 shares of Altimmune, Inc. at $1.64 a share, worth $16.4K in total on Nov 13, 2026. Shares held after the trade: 58,800 (+20.5%).

Value
$16.4K
Shares
10,000
Price
$1.64
Role
Director
Holding change
+20.5%
Trade date
Nov 13, 2026
4:27 PM ET Form 4
Insider Buying Aldeyra Therapeutics, Inc. ALDX

Aldeyra Therapeutics Director Richard Douglas Buys $129K of Stock

Richard Douglas, Director, bought 200,000 shares of Aldeyra Therapeutics, Inc. at $0.6445 a share, worth $129K in total on Nov 11, 2026. Shares held after the trade: 395,000 (+102.6%).

Value
$129K
Shares
200,000
Price
$0.6445
Role
Director
Holding change
+102.6%
Trade date
Nov 11, 2026
4:27 PM ET 8-K
Dividend Cinemark Holdings, Inc. CNK

Cinemark Holdings Dividend

Cinemark Holdings, Inc. declared a quarterly cash dividend of $0.09 per share of common stock. The dividend is scheduled to be paid on December 9, 2026, to stockholders of record as of November 25, 2026.

4:27 PM ET 8-K
Business Update Ares Industrial Real Estate Income Trust Inc.

Ares Industrial Real Estate Income Trust Business Update

Ares Industrial Real Estate Income Trust reported its monthly Net Asset Value (NAV) as of October 31, 2026, with an Aggregate Fund NAV of approximately $5.31 billion. The transaction price for December 1, 2026, will be based on this updated NAV per share calculation. The filing also details the company's total investment portfolio of $10.36 billion, which includes industrial properties, joint ventures, and real estate debt.

4:27 PM ET Form 4
Insider Buying Altimmune, Inc. ALT

Altimmune President and CEO Jerome Benedict Durso Buys $49.7K of Stock

Jerome Benedict Durso, President and CEO, bought 30,700 shares of Altimmune, Inc. at $1.62 a share, worth $49.7K in total on Nov 13, 2026. Shares held after the trade: 93,200 (+49.1%).

Value
$49.7K
Shares
30,700
Price
$1.62
Role
President and CEO
Holding change
+49.1%
Trade date
Nov 13, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.